227 related articles for article (PubMed ID: 12794247)
1. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Jatoi A; Tirona MT; Cha SS; Alberts SR; Rowland KM; Morton RF; Nair S; Kardinal CG; Stella PJ; Mailliard JA; Sargen D; Goldberg RM
Int J Gastrointest Cancer; 2002; 32(2-3):115-23. PubMed ID: 12794247
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.
Hecht JR; Blanke CD; Benson AB; Lenz HJ
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):13-5. PubMed ID: 14569841
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
Jatoi A; Murphy BR; Foster NR; Nikcevich DA; Alberts SR; Knost JA; Fitch TR; Rowland KM;
Ann Oncol; 2006 Jan; 17(1):29-34. PubMed ID: 16303863
[TBL] [Abstract][Full Text] [Related]
4. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Di Lauro L; Nunziata C; Arena MG; Foggi P; Sperduti I; Lopez M
Br J Cancer; 2007 Sep; 97(5):593-7. PubMed ID: 17667920
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
Govindan R; Read W; Faust J; Trinkaus K; Ma MK; Baker SD; McLeod HL; Perry MC
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):27-31. PubMed ID: 14569845
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Blanke CD; Haller DG; Benson AB; Rothenberg ML; Berlin J; Mori M; Hsieh YC; Miller LL
Ann Oncol; 2001 Nov; 12(11):1575-80. PubMed ID: 11822757
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.
Kurtz JE; Négrier S; Husseini F; Limacher JM; Borel C; Wagner JP; Prévot G; Bergerat JP; Dufour P
Hepatogastroenterology; 2003; 50(50):567-70. PubMed ID: 12749274
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Lordick F; von Schilling C; Bernhard H; Hennig M; Bredenkamp R; Peschel C
Br J Cancer; 2003 Aug; 89(4):630-3. PubMed ID: 12915869
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
Sym SJ; Chang HM; Kang HJ; Lee SS; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2008 Dec; 63(1):1-8. PubMed ID: 18288477
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Fujita A; Ohkubo T; Hoshino H; Takabatake H; Tagaki S; Sekine K
Anticancer Drugs; 2002 Jun; 13(5):505-9. PubMed ID: 12045462
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
Enzinger PC; Kulke MH; Clark JW; Ryan DP; Kim H; Earle CC; Vincitore MM; Michelini AL; Mayer RJ; Fuchs CS
Dig Dis Sci; 2005 Dec; 50(12):2218-23. PubMed ID: 16416165
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR
Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688
[TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Earle CC; Kulke MH; Meyerhardt JA; Blaszkowsky LS; Zhu AX; Fidias P; Vincitore MM; Mayer RJ; Fuchs CS
Ann Oncol; 2009 Mar; 20(3):475-80. PubMed ID: 19139178
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Rocha Lima CM; Urbanic JJ; Sherman CA; Brescia FJ; Green MR
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):37-45. PubMed ID: 11221020
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Giordano KF; Jatoi A; Stella PJ; Foster N; Tschetter LK; Alberts SR; Dakhil SR; Mailliard JA; Flynn PJ; Nikcevich DA;
Ann Oncol; 2006 Apr; 17(4):652-6. PubMed ID: 16497828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
